Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -0.37% | 333.61 | 0.0% | $4529.69m | |
| NVAX | Novavax, Inc. | -3.43% | 160.55 | 79.4% | $722.22m | |
| BNTX | BioNTech SE | 0.67% | 262.85 | 0.0% | $709.55m | |
| AMGN | Amgen, Inc. | 1.80% | 206.78 | 1.4% | $547.92m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -1.92% | 6.14 | 0.7% | $429.21m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.59% | 552.11 | 2.7% | $426.22m | |
| GILD | Gilead Sciences, Inc. | 1.52% | 66.90 | 1.0% | $414.02m | |
| CCXI | ChemoCentryx, Inc. | 3.76% | 33.65 | 2.9% | $399.69m | |
| ILMN | Illumina, Inc. | 0.87% | 414.08 | 3.3% | $377.90m | |
| XLRN | Acceleron Pharma, Inc. | 0.43% | 173.74 | 5.3% | $364.00m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 2.55% | 185.41 | 1.9% | $264.85m | |
| BIIB | Biogen, Inc. | -0.59% | 268.13 | 1.7% | $232.27m | |
| OCGN | Ocugen, Inc. | 0.85% | 8.33 | 0.0% | $180.05m | |
| XENE | Xenon Pharmaceuticals, Inc. | -2.96% | 29.81 | 0.4% | $166.66m | |
| DNA | Ginkgo Bioworks Holdings, Inc. | 20.21% | 14.81 | 0.0% | $162.54m |
Company Profile
BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.